Camp4 Therapeutics (CAMP) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on RNA-targeting therapeutics to upregulate gene expression for genetic diseases.

• Lead candidate CMP-002 targets SYNGAP1-related disorder, a severe developmental and epileptic encephalopathy with no approved disease-modifying therapies.

• Proprietary RAP Platform enables identification of regulatory RNAs to amplify mRNA expression and generate antisense oligonucleotide (ASO) candidates.

• Primary focus on central nervous system diseases, with additional discovery programs and strategic partnerships to expand platform applications.

Financial performance and metrics

• Initial private placement in September 2025 raised $46.7 million net, with a second closing in August 2026 raising $50.1 million gross before fees.

• 62,753,200 shares of common stock outstanding as of August 3, 2026.

Use of proceeds and capital allocation

• No proceeds from resale of shares by selling stockholders; company will only receive proceeds from cash exercise of pre-funded warrants.

• Any net proceeds from warrant exercises will fund preclinical and clinical development of CMP-002, working capital, and general corporate purposes.